149 related articles for article (PubMed ID: 11524476)
1. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis.
Tomaszewski KJ; Holloway RG
Neurology; 2001 Aug; 57(4):663-71. PubMed ID: 11524476
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Deep Brain Stimulation in Patients with Parkinson's Disease in Japan.
Kawamoto Y; Mouri M; Taira T; Iseki H; Masamune K
World Neurosurg; 2016 May; 89():628-635.e1. PubMed ID: 26704203
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease.
Dams J; Siebert U; Bornschein B; Volkmann J; Deuschl G; Oertel WH; Dodel R; Reese JP
Mov Disord; 2013 Jun; 28(6):763-71. PubMed ID: 23576266
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of subthalmic nucleus deep brain stimulation for the treatment of advanced Parkinson disease in Hong Kong: a prospective study.
Zhu XL; Chan DT; Lau CK; Poon WS; Mok VC; Chan AY; Wong LK; Yeung JH; Leung MC; Tang VY; Wong RK; Yeung C
World Neurosurg; 2014 Dec; 82(6):987-93. PubMed ID: 25175275
[TBL] [Abstract][Full Text] [Related]
6. Economic Analysis of Deep Brain Stimulation in Parkinson Disease: Systematic Review of the Literature.
Becerra JE; Zorro O; Ruiz-Gaviria R; Castañeda-Cardona C; Otálora-Esteban M; Henao S; Navarrete S; Acevedo JC; Rosselli D
World Neurosurg; 2016 Sep; 93():44-9. PubMed ID: 27216925
[TBL] [Abstract][Full Text] [Related]
7. Deep Brain Stimulation for Parkinson's Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis.
Fundament T; Eldridge PR; Green AL; Whone AL; Taylor RS; Williams AC; Schuepbach WM
PLoS One; 2016; 11(7):e0159340. PubMed ID: 27441637
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Deep Brain Stimulation for Advanced Parkinson's Disease in the United States.
Pietzsch JB; Garner AM; Marks WJ
Neuromodulation; 2016 Oct; 19(7):689-697. PubMed ID: 27491661
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of neurostimulation in Parkinson's disease with early motor complications.
Dams J; Balzer-Geldsetzer M; Siebert U; Deuschl G; Schuepbach WM; Krack P; Timmermann L; Schnitzler A; Reese JP; Dodel R;
Mov Disord; 2016 Aug; 31(8):1183-91. PubMed ID: 27506638
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Deep Brain Stimulation for Parkinson Disease in Taiwan.
Fann JC; Chang KC; Yen AM; Chen SL; Chiu SY; Chen HH; Liou HH
World Neurosurg; 2020 Jun; 138():e459-e468. PubMed ID: 32147563
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's disease.
Eggington S; Valldeoriola F; Chaudhuri KR; Ashkan K; Annoni E; Deuschl G
J Neurol; 2014 Jan; 261(1):106-16. PubMed ID: 24158271
[TBL] [Abstract][Full Text] [Related]
12. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease.
Valldeoriola F; Morsi O; Tolosa E; Rumià J; Martí MJ; Martínez-Martín P
Mov Disord; 2007 Nov; 22(15):2183-91. PubMed ID: 17724747
[TBL] [Abstract][Full Text] [Related]
13. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
Noyes K; Dick AW; Holloway RG;
Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of deep brain stimulation surgery plus best medical therapy versus best medical therapy in patients with Parkinson's: Economic evaluation alongside the PD SURG trial.
McIntosh E; Gray A; Daniels J; Gill S; Ives N; Jenkinson C; Mitchell R; Pall H; Patel S; Quinn N; Rick C; Wheatley K; Williams A;
Mov Disord; 2016 Aug; 31(8):1173-82. PubMed ID: 26846185
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis of Parkinson's disease.
Shan DE; Wu HC; Chan LY; Liu KD
Acta Neurol Taiwan; 2011 Mar; 20(1):65-72. PubMed ID: 21249581
[TBL] [Abstract][Full Text] [Related]
16. [Review of the economic evidence on the use of deep brain stimulation in late stage Parkinson's disease].
Puig-Junoy J; Puig Peiró R
Neurologia; 2009 May; 24(4):220-9. PubMed ID: 19603291
[TBL] [Abstract][Full Text] [Related]
17. Deep Brain Stimulation for Advanced Parkinson Disease in Developing Countries: A Cost-Effectiveness Study From China.
Guo X; Feng C; Pu J; Jiang H; Zhu Z; Zheng Z; Zhang J; Chen G; Zhu J; Wu H
Neurosurgery; 2023 Apr; 92(4):812-819. PubMed ID: 36729808
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease medication use and costs following deep brain stimulation.
Weaver FM; Stroupe KT; Cao L; Holloway RG; Vickrey BG; Simuni T; Hendricks A; Ippolito D
Mov Disord; 2012 Sep; 27(11):1398-403. PubMed ID: 22975928
[TBL] [Abstract][Full Text] [Related]
19. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During MJ; Kaplitt MG; Stern MB; Eidelberg D
Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of deep brain stimulation compared with vagus nerve stimulation and usual care for patients with refractory epilepsy: A lifetime decision analytic model.
Chan HY; Wijnen BFM; Majoie MHJM; Evers SMAA; Hiligsmann M
Epilepsia; 2022 Mar; 63(3):641-651. PubMed ID: 34967942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
